盐酸文拉法辛联合枸橼酸坦度螺酮治疗血管性抑郁症伴躯体症状障碍患者睡眠障碍的临床随机对照研究

林永森; 林萍珍

doi:10.15912/j.issn.1671-8194.2025.12.004

PDF(859 KB)

中国医药指南 ›› 2025, Vol. 23 ›› Issue (12) : 15-19. DOI: 10.15912/j.issn.1671-8194.2025.12.004

论著

盐酸文拉法辛联合枸橼酸坦度螺酮治疗血管性抑郁症伴躯体症状障碍患者睡眠障碍的临床随机对照研究

林永森¹, 林萍珍^2,*

作者信息 +

A Randomized Controlled Trial of Venlafaxine Hydrochloride Combined with Tandospirone Citrate in the Treatment of Sleep Disorders in Patients with Vascular Depression and Somatic Symptoms Disorder

Yongsen Lin¹, Pingzhen Lin^2,*

Author information +

摘要

目的探究盐酸文拉法辛联合枸橼酸坦度螺酮对血管性抑郁症（VaDep）伴躯体症状障碍患者睡眠障碍的有效性及安全性。方法选择2022年6月至2024年8月福建医科大学附属泉州第一医院神经内科门诊及住院的VaDep患者共93例作为研究对象,随机进入联合治疗组（盐酸文拉法辛+枸橼酸坦度螺酮）和单药治疗组（盐酸文拉法辛）接受治疗。采用汉密尔顿抑郁量表（HAMD）、患者健康问卷15项（PHQ-15）及匹兹堡睡眠质量指数量表（PSQI）评定疗效。结果两组患者在治疗后HAMD、PHQ-15及PSQI评分均较治疗前下降（均P<0.001）。联合治疗组在治疗后第2周及第8周HAMD评分低于单药治疗组,在治疗后第2周、第4周及第8周PHQ-15及PSQI评分低于单药治疗组（均P<0.05）。两组患者药物不良反应无显著性差异（P=0.759）。结论盐酸文拉法辛能有效改善VaDep伴躯体化障碍患者的睡眠障碍,枸橼酸坦度螺酮能增强这种效果。

Abstract

Objective s To investigate the efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate in the treatment of sleep disorders in patients with vascular depression (VaDep) and somatic symptoms disorder. Methods From June 2022 to August 2024, 93 patients with VaDep in the neurology clinic and inpatient department of the First Affiliated Hospital of Quanzhou, Fujian Medical University were selected as study subjects and randomly divided into the combined treatment group (venlafaxine hydrochloride + tandospirone citrate) and the monotherapy group (venlafaxine hydrochloride) for treatment. Hamilton Depression Rating Scale (HAMD), 15-item Patient Health Questionnaire (PHQ-15) and Pittsburgh Sleep Quality Index (PSQI) were used to assess efficacy. Results The HAMD, PHQ-15 and PSQI scores in both groups were lower after treatment than before treatment (all P<0.001). The HAMD scores of the combined treatment group were lower than those of the monotherapy group at weeks 2 and 8 after treatment, and the PHQ-15 and PSQI scores were lower than those of the monotherapy group at weeks 2, 4 and 8 after treatment (all P<0.05). Adverse drug reactions were not significantly different between the two groups (P=0.759). Conclusions Venlafaxine hydrochloride can effectively improve sleep disorders in patients with VaDep and somatic symptoms disorder, and tandospirone citrate can enhance this effect.

导出引用

林永森, 林萍珍. 盐酸文拉法辛联合枸橼酸坦度螺酮治疗血管性抑郁症伴躯体症状障碍患者睡眠障碍的临床随机对照研究[J]. 中国医药指南. 2025, 23(12): 15-19 https://doi.org/10.15912/j.issn.1671-8194.2025.12.004

Yongsen Lin, Pingzhen Lin. A Randomized Controlled Trial of Venlafaxine Hydrochloride Combined with Tandospirone Citrate in the Treatment of Sleep Disorders in Patients with Vascular Depression and Somatic Symptoms Disorder[J]. Guide of China Medicine. 2025, 23(12): 15-19 https://doi.org/10.15912/j.issn.1671-8194.2025.12.004

中图分类号： R749.3

参考文献

[1] Alexopoulos GS,Meyers BS,Young RC,et al.Clinically defined vascular depression[J]. Am J Psychiatry,1997,154(4):562-565.
[2] Krishnan KR,Hays JC,Blazer DG.MRI-defined vascular depression[J]. Am J Psychiatry,1997,154(4):497-501.
[3] Gonzalez HM,Tarraf W,Whitfield K,et al.Vascular depression prevalence and epidemiology in the United States[J]. J Psychiatr Res,2012,46(4):456-461.
[4] Taylor WD,Schultz SK,Panaite V,et al.Perspectives on the Management of Vascular Depression[J]. Am J Psychiatry,2018,175(12):1169-1175.
[5] Aizenstein HJ,Baskys A,Boldrini M,et al.Vascular depression consensus report - a critical update[J]. BMC Med,2016,14(1):161.
[6] P H.Management of somatic symptom disorder[J]. Dialogues Clin Neurosci,2018,20(1):23-31.
[7] Steffens DC.Vascular Depression:Is an Old Research Construct Finally Ready for Clinical Prime Time?[J]. Biol Psychiatry,2019,85(6):441-442.
[8] 陈梦云,袁勇贵. 躯体症状障碍的诊断与治疗进展[J]. 实用老年医学,2019,33(10):939-943.
[9] Riemann D,Krone LB,Wulff K,et al.Sleep,insomnia,and depression[J]. Neuropsychopharmacology,2019,45(1):74-89.
[10] 傅燚,陈诗恩,崔海松,等. 团体艺术治疗联合盐酸文拉法辛对伴有躯体症状围绝经期抑郁障碍患者的疗效观察[J]. 同济大学学报(医学版),2020,41(6):717-721.
[11] 邓倩曦,邹龙. 莫沙必利、舒必利及坦度螺酮联合治疗以腹胀为主躯体化障碍43例疗效观察[J]. 安徽医药,2020,24(3):576-579.
[12] 钱昌,陈蕴辉. 舒肝解郁胶囊联合坦度螺酮治疗门诊老年抑郁症的疗效及对患者睡眠质量的影响[J]. 现代中西医结合杂志,2018,27(36):4061-4064.
[13] Chen H,Lin Y,Zhao Z,et al.Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms:An open‐labeled randomized control trial[J]. CNS Neurosci Ther,2024,30(3):e14650.
[14] American Psychiatric A.In:Diagnostic and Statistical Manual of Mental Disorders,Text Revision (DSM-IV-TR),fourth ed[M]. Washington,DC:American Psychiatric Association,2000.
[15] Zimmerman M,Martinez JH,Young D,et al.Severity classification on the Hamilton Depression Rating Scale[J]. J Affect Disord,2013,150(2):384-388.
[16] Liao SC,Huang WL,Ma HM,et al.The relation between the patient health questionnaire-15 and DSM somatic diagnoses[J]. BMC Psychiatry,2016,16(1):351.
[17] Fazekas FC J,Alavi A,Hurtig HI,Zimmerman RA.MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging[J]. AJR Am J Roentgenol,1987,149(2):351-356.
[18] Nishiyama T,Mizuno T,Kojima M,et al.Criterion validity of the Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale for the diagnosis of sleep disorders[J]. Sleep Med,2014,15(4):422-429.
[19] de Beurs E,Carlier IVE,van Hemert AM. Approaches to denote treatment outcome:Clinical significance and clinical global impression compared[J]. Int J Methods Psychiatr Res,2019,28(4).
[20] Ahmadimanesh M,Balarastaghi S,Rashedinia M,et al.A systematic review on the genotoxic effect of serotonin and norepinephrine reuptake inhibitors (SNRIs) antidepressants[J]. Psychopharmacology,2020,237(7):1909-1915.
[21] Kang EH,Lee IS,Chung SK,et al.Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder:a randomized,open-labeled trial[J]. Psychiatry Res,2009,169(2):118-23.
[22] 程丹,,官丹蕊,傅启伟. 文拉法辛对产后抑郁患者情绪、睡眠及认知功能的影响[J]. 国际精神病学杂,2024,51(5):1536-1538.
[23] 赵翠,闫凤霞,曹俊杰,等. 枸橼酸坦度螺酮治疗阿尔茨海默病伴发抑郁焦虑障碍的效果观察[J]. 山东医药,2015,55(29):45-6.
[24] Chen H,Lin Q,Lin T,et al.A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression:A pilot randomized controlled trial at a single-center in China[J]. J Psychiatr Res,2019,114:133-40.
[25] Mori M,Murata Y,Matsuo A,et al.Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis[J]. Neurol Ther,2014,3(1):67-77.
[26] 储新娟,肖伟忠,李清华,等. 枸橼酸坦度螺酮胶囊治疗神经性头痛50例疗效观察[J]. 现代生物医学进展,2015,15(09):1718-20.